Roche announced that Zelboraf was approved in Canada as monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. Melanoma is the deadliest and most aggressive form of skin cancer, killing 80%-85% of stage IV patients within five years.
European stocks rose for a third straight session on Monday and the euro bounced back from two-year lows, as Greek …
There are no comments yet